Z Gastroenterol 2018; 56(05): 499-506
DOI: 10.1055/s-0043-124874
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS)

Contrast-enhanced ultrasound: Liver Imaging Reporting and Data System (CEUS LI-RADS)
Christoph F. Dietrich
1   Department of Internal Medicine 2, Caritas-Krankenhaus Bad Mergentheim, Germany
,
Andrej Potthoff
2   Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
,
Thomas Helmberger
3   Institute of Diagnostic and Interventional Radiology and Neuroradiology, Klinikum Bogenhausen, Munich, Germany
,
Andre Ignee
1   Department of Internal Medicine 2, Caritas-Krankenhaus Bad Mergentheim, Germany
,
Juergen K. Willmann
4   Department of Radiology; Stanford University; Stanford, CA, USA
,
on behalf of the CEUS LI-RADS Working Group › Author Affiliations
Further Information

Publication History

02 July 2017

11 December 2017

Publication Date:
07 May 2018 (online)

Zusammenfassung

In der Abklärung von hepatozellulären Karzinomen (HCCs) bei Hochrisikopatienten wurde zur standardisierten Befundung und Dokumentation der Kontrastmittel-Computertomografie (CECT) und Kontrastmittel-Magnetresonanztomografie (CEMRT) vor wenigen Jahren das „Liver Imaging Reporting and Data System” (LI-RADS) durch das American College of Radiology (ACR) erstellt. Die LI-RADS-Kategorisierung wird zur Klassifikation von Leberläsionen in der Leberzirrhose als sicher benigne (LR-1), intermediär (LR2 – 4) bis zu „definitiv HCC“ (LR-5) beurteilt. Seit 2014 wurde die LI-RADS-Klassifikation durch eine Arbeitsgruppe von internationalen Radiologen und Hepatologen auf die Kontrastmittelsonografie erweitert. Zeitgleich mit der Zulassung des Kontrastmittels SonoVue™ (in den USA Lumason™) wurde die Klassifikation 2016 in die LI-RADS Kategorisierung integriert und wird in diesem Artikel erläutert (CEUS-LI-RADS).

Abstract

The American College of Radiology (ACR) endorsed the Liver Imaging Reporting and Data System (LI-RADS) for standardized reporting and data collection of computed tomography (CT) and magnetic resonance (MR) imaging for hepatocellular carcinoma (HCC) in high-risk patients (liver cirrhosis). The LI-RADS imaging criteria are used to classify ‘observations’ from ‘definitely benign’ (LR-1) to ‘definitely HCC’ (LR-5) based on imaging criteria.

Coincidently, the recent approval in the United States of a microbubble contrast agent for liver imaging (Lumason®, known as SonoVue® in Europe and elsewhere), LI-RADS. is being expanded to include contrast-enhanced ultrasound (CEUS). An international working group was initiated in 2014. Herewith, the most current version of CEUS-LI-RADS is presented.

 
  • Literatur

  • 1 European Association For The Study Of The Liver, European Organisation For Research and Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
  • 2 European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48: 599-641
  • 3 Heimbach J, Kulik LM, Finn R. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
  • 4 Greten TF, Malek NP, Schmidt S. et al. Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 2013; 51: 1269-1326
  • 5 Barth BK, Donati OF, Fischer MA. et al. Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis. Acad Radiol 2016; 23: 1145-1153
  • 6 Tanabe M, Kanki A, Wolfson T. et al. Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. Radiology 2016; 281: 129-139
  • 7 Shah A, Tang A, Santillan C. et al. Cirrhotic liver: What’s that nodule? The LI-RADS approach. J Magn Reson Imaging 2016; 43: 281-294
  • 8 Mitchell DG, Bruix J, Sherman M. et al. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065
  • 9 Bashir MR, Huang R, Mayes N. et al. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging 2015; 42: 305-314
  • 10 Santillan CS, Tang A, Cruite I. et al. Understanding LI-RADS: a primer for practical use. Magn Reson Imaging Clin N Am 2014; 22: 337-352
  • 11 Jha RC, Mitchell DG, Weinreb JC. et al. LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. Am J Roentgenol 2014; 203: W48-W69
  • 12 Claudon M, Dietrich CF, Choi BI. et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013; 34: 11-29
  • 13 Claudon M, Dietrich CF, Choi BI. et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013; 39: 187-210
  • 14 Claudon M, Cosgrove D, Albrecht T. et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008. Ultraschall Med 2008; 29: 28-44
  • 15 Albrecht T, Blomley M, Bolondi L. et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25: 249-256
  • 16 Ignee A, Atkinson NS, Schuessler G. et al. Ultrasound contrast agents. Endosc Ultrasound 2016; 5: 355-362
  • 17 Chiorean L, Tana C, Braden B. et al. Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines. Med Princ Pract 2016; 25: 399-407
  • 18 Chiorean L, Cantisani V, Jenssen C. et al. Focal masses in a non-cirrhotic liver: The additional benefit of CEUS over baseline imaging. Eur J Radiol 2015; 84: 1636-1643
  • 19 Chiorean L, Caraiani C, Radzina M. et al. Vascular phases in imaging and their role in focal liver lesions assessment. Clin Hemorheol Microcirc 2015; 62: 299-326
  • 20 Kono Y, Lyshchik A, Cosgrove D. et al. Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS[R]): the official version by the American College of Radiology (ACR). Ultraschall Med 2017; 38: 85-86
  • 21 Dietrich CF, Maddalena ME, Cui XW. et al. Liver tumor characterization--review of the literature. Ultraschall Med 2012; 33 (Suppl. 01) S3-S10
  • 22 Dietrich CF. Liver tumor characterization--comments and illustrations regarding guidelines. Ultraschall Med 2012; 33 (Suppl. 01) S22-S30
  • 23 Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57: 930-932
  • 24 Dietrich CF, Sharma M, Gibson RN. et al. Fortuitously discovered liver lesions. World J Gastroenterol 2013; 19: 3173-3188
  • 25 Dietrich CF, Jenssen C. Focal liver lesion, incidental finding. Dtsch Med Wochenschr 2012; 137: 2099-2116
  • 26 Piscaglia F, Wilson SR, Lyshchik A. et al. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall Med 2017; 38: 320-324
  • 27 Dietrich CF, Kono Y, Dietrich CF. et al. Contrast-Enhanced Ultrasound: Liver Imaging Reporting and Data System (CEUS LI-RADS). In 2016 http://www.solutionsincontrastimaging.com/
  • 28 Dietrich CF, Lorentzen T, Appelbaum L. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Short Version). Ultraschall Med 2016; 37: 27-45
  • 29 Dietrich CF, Lorentzen T, Appelbaum L. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Long Version). Ultraschall Med 2016; 37: E1-E32
  • 30 Sidhu PS, Brabrand K, Cantisani V. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part II. Diagnostic Ultrasound-Guided Interventional Procedures (Long Version). Ultraschall Med 2015; 36: E15-E35
  • 31 Sidhu PS, Brabrand K, Cantisani V. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part II. Diagnostic Ultrasound-Guided Interventional Procedures (Short Version). Ultraschall Med 2015; 36: 566-580
  • 32 Dietrich CF, Lorentzen T, Sidhu PS. et al. An Introduction to the EFSUMB Guidelines on Interventional Ultrasound (INVUS). Ultraschall Med 2015; 36: 460-463
  • 33 Lorentzen T, Nolsoe CP, Ewertsen C. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (long Version). Ultraschall Med 2015; 36: E1-E14
  • 34 Lorentzen T, Nolsoe CP, Ewertsen C. et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (Short Version). . Ultraschall Med 2015; 36: 464-472
  • 35 Meloni MF, Galimberti S, Dietrich CF. et al. Microwave ablation of hepatic tumors with a third generation system: locoregional efficacy in a prospective cohort study with intermediate term follow-up. Z Gastroenterol 2016; 54: 541-547
  • 36 Dietrich CF, Cui XW, Chiorean L. et al. Local ablative procedures of the liver. Z Gastroenterol 2015; 53: 579-590
  • 37 Dietrich CF, Averkiou MA, Correas JM. et al. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012; 33: 344-351
  • 38 Dietrich CF, Dong Y, Froehlich E. et al. Dynamic contrast-enhanced endoscopic ultrasound: A quantification method. Endosc Ultrasound 2017; 6: 12-20
  • 39 Frohlich E, Muller R, Cui XW. et al. Dynamic contrast-enhanced ultrasound for quantification of tissue perfusion. J Ultrasound Med 2015; 34: 179-196
  • 40 Dietrich CF, Cui XW, Barreiros AP. et al. EFSUMB guidelines 2011: comment on emergent indications and visions. Ultraschall Med 2012; 33 (Suppl. 01) S39-S47
  • 41 Dietrich CF, Cui XW, Schreiber-Dietrich DG. et al. EFSUMB guidelines 2011: comments and illustrations. Ultraschall Med 2012; 33 (Suppl. 01) S11-S21
  • 42 Piscaglia F, Kudo M, Han KH. et al. Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria. Ultraschall Med 2017; 38: 9-11
  • 43 Wildner D, Bernatik T, Greis C. et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015; 36: 132-139
  • 44 Bruix J, Sherman M. Management of hepatocellular carcinoma: anupdate. Hepatology 2011; 53: 1020-1022
  • 45 Darnell A, Forner A, Rimola J. et al. Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology 2015; 275: 698-707
  • 46 Matsui O, Kobayashi S, Sanada J. et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 2011; 36: 264-272
  • 47 Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007; 17: 2969-2982
  • 48 Forner A, Vilana R, Ayuso C. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104
  • 49 Iavarone M, Sangiovanni A, Forzenigo LV. et al. Diagnosis of Hepatocellular Carcinoma in Cirrhosis by Dynamic Contrast Imaging: The Importance of Tumor Cell Differentiation. Hepatology 2010; 52: 1723-1730
  • 50 Bolondi L, Gaiani S, Celli N. et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34
  • 51 Ignee A, Weiper D, Schuessler G. et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z Gastroenterol 2005; 43: 289-294
  • 52 Dietrich CF, Greis C. How to perform contrast enhanced ultrasound. Dtsch Med Wochenschr 2016; 141: 1019-1024
  • 53 Dietrich CF, Mertens JC, Braden B. et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45: 1139-1145
  • 54 Dietrich CF, Schuessler G, Trojan J. et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78: 704-707
  • 55 Dietrich CF, Ignee A, Trojan J. et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53: 401-405
  • 56 Strobel D, Seitz K, Blank W. et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008; 29: 499-505
  • 57 Friedrich-Rust M, Klopffleisch T, Nierhoff J. et al. Contrast-Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a meta-analysis. Liver Int 2013; 33: 739-755
  • 58 Boozari B, Soudah B, Rifai K. et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography – a prospective study. Dig Liver Dis 2011; 43: 484-490
  • 59 Tang A, Bashir MR, Corwin MT. et al. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 2018; 286: 29-48
  • 60 Lyshchik A, Kono Y, Dietrich CF. et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY); 2017 (epub in advance)
  • 61 Kim TK, Noh SY, Wilson SR. et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017; 23: 280-289
  • 62 Wilson SR, Lyshchik A, Piscaglia F. et al. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol (NY) 2018; 43: 127-142
  • 63 Piscaglia F, Wilson SR, Lyshchik A. et al. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall Med 2017; 38: 320-324
  • 64 Hirche TO, Ignee A, Hirche H. et al. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 2007; 27: 748-757
  • 65 Dietrich CF, Ignee A, Greis C. et al. Artifacts and pitfalls in contrast-enhanced ultrasound of the liver. Ultraschall Med 2014; 35: 108-125 quiz 126–107
  • 66 Dietrich CF, Ignee A, Hocke M. et al. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol 2011; 49: 350-356
  • 67 Dietrich CF, Averkiou M, Nielsen MB. et al. How to perform Contrast-Enhanced Ultrasound (CEUS). Ultrasound Int Open 2018; 4: E2-E15
  • 68 Berzigotti A, Ferraioli G, Bota S. et al. Novel ultrasound-based methods to assess liver disease: The game has just begun. Dig Liver Dis 2018; 50: 107-112